Approximately, non-PTK mutation accounted for ~75% of ROS1 mutation in melanoma patients, namely 79.0% (n = 49) in the MSK ICI-treated melanoma population and 75.0% (n = 15) in the MEL-IPI cohort (Figures 5B, C). Here, ROS1 is linked to melanoma.